Illumina, Inc. (0J8Z.L)
USD 70.61
(-3.17%)
USD 70.61
(-3.17%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 587 Million USD | 3.35% |
| 2022 | 568 Million USD | 31.79% |
| 2021 | 431 Million USD | 15.86% |
| 2020 | 372 Million USD | 3.62% |
| 2019 | 359 Million USD | -6.99% |
| 2018 | 386 Million USD | 15.92% |
| 2017 | 333 Million USD | 10.94% |
| 2016 | 300.17 Million USD | 10.86% |
| 2015 | 270.77 Million USD | 41.66% |
| 2014 | 191.14 Million USD | 24.04% |
| 2013 | 154.09 Million USD | -2.91% |
| 2012 | 158.71 Million USD | 23.25% |
| 2011 | 128.78 Million USD | -9.44% |
| 2010 | 142.21 Million USD | 53.28% |
| 2009 | 92.77 Million USD | 26.34% |
| 2008 | 73.43 Million USD | 36.03% |
| 2007 | 53.98 Million USD | 167.64% |
| 2006 | 20.16 Million USD | 95.64% |
| 2005 | 10.3 Million USD | 170.79% |
| 2004 | 3.8 Million USD | 88.28% |
| 2003 | 2.02 Million USD | -12.05% |
| 2002 | 2.29 Million USD | 136.77% |
| 2001 | 971 Thousand USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 584 Million USD | -0.51% |
| 2024 Q3 | 574 Million USD | 2.32% |
| 2024 Q2 | 561 Million USD | -3.94% |
| 2023 Q4 | 587 Million USD | -4.55% |
| 2023 Q3 | 615 Million USD | -0.32% |
| 2023 FY | 587 Million USD | 3.35% |
| 2023 Q1 | 586 Million USD | 3.17% |
| 2023 Q2 | 617 Million USD | 5.29% |
| 2022 Q3 | 559 Million USD | 7.92% |
| 2022 Q4 | 568 Million USD | 1.61% |
| 2022 FY | 568 Million USD | 31.79% |
| 2022 Q1 | 465 Million USD | 7.89% |
| 2022 Q2 | 518 Million USD | 11.4% |
| 2021 Q2 | 380 Million USD | 4.4% |
| 2021 FY | 431 Million USD | 15.86% |
| 2021 Q1 | 364 Million USD | -2.15% |
| 2021 Q4 | 431 Million USD | 7.48% |
| 2021 Q3 | 401 Million USD | 5.53% |
| 2020 FY | 372 Million USD | 3.62% |
| 2020 Q1 | 384 Million USD | 6.96% |
| 2020 Q2 | 435 Million USD | 13.28% |
| 2020 Q4 | 372 Million USD | -10.36% |
| 2020 Q3 | 415 Million USD | -4.6% |
| 2019 Q4 | 359 Million USD | -13.91% |
| 2019 FY | 359 Million USD | -6.99% |
| 2019 Q3 | 417 Million USD | -0.71% |
| 2019 Q1 | 412 Million USD | 6.74% |
| 2019 Q2 | 420 Million USD | 1.94% |
| 2018 FY | 386 Million USD | 15.92% |
| 2018 Q1 | 350 Million USD | 5.11% |
| 2018 Q2 | 362 Million USD | 3.43% |
| 2018 Q3 | 374 Million USD | 3.31% |
| 2018 Q4 | 386 Million USD | 3.21% |
| 2017 Q1 | 299 Million USD | -0.39% |
| 2017 Q4 | 333 Million USD | 1.83% |
| 2017 Q3 | 327 Million USD | 5.83% |
| 2017 Q2 | 309 Million USD | 3.34% |
| 2017 FY | 333 Million USD | 10.94% |
| 2016 FY | 300.17 Million USD | 10.86% |
| 2016 Q4 | 300.17 Million USD | -3.87% |
| 2016 Q3 | 312.24 Million USD | 0.28% |
| 2016 Q2 | 311.36 Million USD | 8.14% |
| 2016 Q1 | 287.91 Million USD | 6.33% |
| 2015 Q1 | 205.18 Million USD | 7.35% |
| 2015 FY | 270.77 Million USD | 41.66% |
| 2015 Q2 | 223.62 Million USD | 8.99% |
| 2015 Q4 | 270.77 Million USD | 15.83% |
| 2015 Q3 | 233.78 Million USD | 4.54% |
| 2014 Q3 | 199.29 Million USD | 12.26% |
| 2014 FY | 191.14 Million USD | 24.04% |
| 2014 Q4 | 191.14 Million USD | -4.09% |
| 2014 Q2 | 177.53 Million USD | 8.1% |
| 2014 Q1 | 164.23 Million USD | 6.57% |
| 2013 FY | 154.09 Million USD | -2.91% |
| 2013 Q4 | 154.09 Million USD | -3.61% |
| 2013 Q1 | 167.95 Million USD | 5.82% |
| 2013 Q2 | 168.07 Million USD | 0.07% |
| 2013 Q3 | 159.86 Million USD | -4.88% |
| 2012 FY | 158.71 Million USD | 23.25% |
| 2012 Q1 | 128.68 Million USD | -0.08% |
| 2012 Q3 | 147.68 Million USD | 10.34% |
| 2012 Q4 | 158.71 Million USD | 7.47% |
| 2012 Q2 | 133.84 Million USD | 4.01% |
| 2011 Q3 | 139.26 Million USD | -2.33% |
| 2011 FY | 128.78 Million USD | -9.44% |
| 2011 Q4 | 128.78 Million USD | -7.53% |
| 2011 Q2 | 142.58 Million USD | -5.39% |
| 2011 Q1 | 150.7 Million USD | 5.97% |
| 2010 Q4 | 142.21 Million USD | 9.37% |
| 2010 FY | 142.21 Million USD | 53.28% |
| 2010 Q3 | 130.02 Million USD | 8.86% |
| 2010 Q1 | 100.62 Million USD | 8.46% |
| 2010 Q2 | 119.44 Million USD | 18.71% |
| 2009 Q4 | 92.77 Million USD | 14.75% |
| 2009 FY | 92.77 Million USD | 26.34% |
| 2009 Q1 | 69.18 Million USD | -5.79% |
| 2009 Q2 | 70.66 Million USD | 2.15% |
| 2009 Q3 | 80.84 Million USD | 14.41% |
| 2008 Q1 | 54.81 Million USD | 1.55% |
| 2008 Q3 | 72.95 Million USD | 7.33% |
| 2008 Q4 | 73.43 Million USD | 0.66% |
| 2008 FY | 73.43 Million USD | 36.03% |
| 2008 Q2 | 67.97 Million USD | 24.0% |
| 2007 Q3 | 45.24 Million USD | 5.47% |
| 2007 Q1 | 36.34 Million USD | 80.18% |
| 2007 FY | 53.98 Million USD | 167.64% |
| 2007 Q2 | 42.89 Million USD | 18.05% |
| 2007 Q4 | 53.98 Million USD | 19.31% |
| 2006 FY | 20.16 Million USD | 95.64% |
| 2006 Q2 | 17.32 Million USD | 34.02% |
| 2006 Q1 | 12.92 Million USD | 25.39% |
| 2006 Q3 | 19.39 Million USD | 11.97% |
| 2006 Q4 | 20.16 Million USD | 3.98% |
| 2005 Q2 | 5.15 Million USD | 3.58% |
| 2005 FY | 10.3 Million USD | 170.79% |
| 2005 Q4 | 10.3 Million USD | 43.94% |
| 2005 Q3 | 7.16 Million USD | 38.88% |
| 2005 Q1 | 4.97 Million USD | 30.79% |
| 2004 FY | 3.8 Million USD | 88.28% |
| 2004 Q3 | 3.18 Million USD | 14.91% |
| 2004 Q2 | 2.77 Million USD | 28.84% |
| 2004 Q4 | 3.8 Million USD | 19.6% |
| 2004 Q1 | 2.15 Million USD | 6.33% |
| 2003 Q3 | 2.64 Million USD | 4.42% |
| 2003 Q4 | 2.02 Million USD | -23.58% |
| 2003 FY | 2.02 Million USD | -12.05% |
| 2003 Q1 | 2.34 Million USD | 1.78% |
| 2003 Q2 | 2.53 Million USD | 8.29% |
| 2002 FY | 2.29 Million USD | 136.77% |
| 2002 Q1 | 1.08 Million USD | 11.23% |
| 2002 Q2 | 1.29 Million USD | 20.0% |
| 2002 Q3 | 1.6 Million USD | 24.15% |
| 2002 Q4 | 2.29 Million USD | 42.88% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q4 | 971 Thousand USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 FY | 971 Thousand USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -4781.903% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -2977.165% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -883.315% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -5947.805% |
| bluebird bio, Inc. | 22.91 Million USD | -2461.194% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -20708.224% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | -52.126% |
| Myriad Genetics, Inc. | 20.1 Million USD | -2820.398% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -1432.637% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -658.32% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 92.945% |
| Waters Corporation | 516.23 Million USD | -13.708% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 88.463% |
| Biogen Inc. | 2.52 Billion USD | 76.775% |
| Nektar Therapeutics | 16.1 Million USD | -3545.736% |
| Perrigo Company plc | 1.14 Billion USD | 48.549% |
| Dynavax Technologies Corporation | 53.29 Million USD | -1001.52% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -5559.468% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -1293.968% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 46.983% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -5237.334% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 77.252% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -794.503% |
| FibroGen, Inc. | 41.56 Million USD | -1312.246% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 43.065% |
| OPKO Health, Inc. | 65.69 Million USD | -793.496% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -558.47% |
| Exelixis, Inc. | 17.32 Million USD | -3288.559% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 77.106% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -3778.427% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 24118.003% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 20.547% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -1965.084% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | -81.813% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -7493.79% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | -360.028% |
| Blueprint Medicines Corporation | 21.22 Million USD | -2665.867% |
| Insmed Incorporated | 83.24 Million USD | -605.122% |
| TG Therapeutics, Inc. | 39.82 Million USD | -1374.023% |
| Incyte Corporation | 62.97 Million USD | -832.16% |
| Emergent BioSolutions Inc. | 328.9 Million USD | -78.474% |